Figure 1 | Hypertension Research

Figure 1

From: The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease

Figure 1

Effects of olmesartan add-on therapy on the after-treatment/baseline (A/B) ratios of (a) serum creatinine, (b) eGFR, (c) UPCR and (d) UACR. Forty-six hypertensive patients with CKD were randomly assigned to the olmesartan add-on group (ARB+) or the non-ARB group (ARB−). At baseline and after the 16-week treatment period, measurements were collected. To compare the effects of anti-hypertensive treatment in each group, the values of the variables after the 16-week active treatment period were normalized to the respective variables at baseline and were expressed as the A/B ratio. The values of the A/B ratios are expressed as the mean±s.d.

Back to article page